Stay updated with breaking news from Leland Gershell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript September 5, 2023 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $2.16, expectations were $-2.68. Operator: Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a […]
Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) with an Outperform rating
Operator: Good afternoon, and welcome to Lumos Pharma's Q2 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Operator: Good afternoon and welcome to the Trevi Therapeutics’ Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
It’s been clear for a while now that the stock market is on an upward trajectory, buoyed by a resilient economy and retreating high inflation. The good news, according to John Stoltzfus, Chief Investment Strategist at Oppenheimer, is that the chances of the bull market continuing are more likely than the bears grabbing hold of the narrative once again. “Our appraisal of the market landscape at this time suggests that opportunity outweighs risk as current monetary policy generates a transition fr